{"url_path":"/sec/teva/8-k/2026-09-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","accession_number":"0001193125-26-389264","cik":"0000818686","ticker":"TEVA","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","primary_entity_key":"0000818686","primary_entity_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD"},"word_count":134,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn September 10, 2026, Teva Pharmaceutical Industries Limited (the “Company”) issued a press release announcing the pricing of the Securities (as defined below). A copy of the related press release issued by the Company is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein in its entirety.\n\nThe information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing."}